Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 2005 Oct 14;60(12):992–997. doi: 10.1136/thx.2005.045385

Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease

D Sin 1, L Wu 1, J Anderson 1, N Anthonisen 1, A Buist 1, P Burge 1, P Calverley 1, J Connett 1, B Lindmark 1, R Pauwels 1, D Postma 1, J Soriano 1, W Szafranski 1, J Vestbo 1
PMCID: PMC1747271  PMID: 16227327

Abstract

Background: Clinical studies suggest that inhaled corticosteroids reduce exacerbations and improve health status in chronic obstructive pulmonary disease (COPD). However, their effect on mortality is unknown.

Methods: A pooled analysis, based on intention to treat, of individual patient data from seven randomised trials (involving 5085 patients) was performed in which the effects of inhaled corticosteroids and placebo were compared over at least 12 months in patients with stable COPD. The end point was all-cause mortality.

Results: Overall, 4% of the participants died during a mean follow up period of 26 months. Inhaled corticosteroids reduced all-cause mortality by about 25% relative to placebo. Stratification by individual trials and adjustments for age, sex, baseline post-bronchodilator percentage predicted forced expiratory volume in 1 second, smoking status, and body mass index did not materially change the results (adjusted hazard ratio (HR) 0.73; 95% confidence interval (CI) 0.55 to 0.96). Although there was considerable overlap between subgroups in terms of effect sizes, the beneficial effect was especially noticeable in women (adjusted HR 0.46; 95% CI 0.24 to 0.91) and former smokers (adjusted HR 0.60; 95% CI 0.39 to 0.93).

Conclusions: Inhaled corticosteroids reduce all-cause mortality in COPD. Further studies are required to determine whether the survival benefits persist beyond 2–3 years.

Full Text

The Full Text of this article is available as a PDF (89.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Almagro Pedro, Calbo Esther, Ochoa de Echagüen Anna, Barreiro Bienvenido, Quintana Salvador, Heredia José L., Garau Javier. Mortality after hospitalization for COPD. Chest. 2002 May;121(5):1441–1448. doi: 10.1378/chest.121.5.1441. [DOI] [PubMed] [Google Scholar]
  2. Alsaeedi Abdullah, Sin Don D., McAlister Finlay A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med. 2002 Jul;113(1):59–65. doi: 10.1016/s0002-9343(02)01143-9. [DOI] [PubMed] [Google Scholar]
  3. Antó J. M., Vermeire P., Vestbo J., Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J. 2001 May;17(5):982–994. doi: 10.1183/09031936.01.17509820. [DOI] [PubMed] [Google Scholar]
  4. Ardies C. Murray. Inflammation as cause for scar cancers of the lung. Integr Cancer Ther. 2003 Sep;2(3):238–246. doi: 10.1177/1534735403256332. [DOI] [PubMed] [Google Scholar]
  5. Barnes P. J., Shapiro S. D., Pauwels R. A. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003 Oct;22(4):672–688. doi: 10.1183/09031936.03.00040703. [DOI] [PubMed] [Google Scholar]
  6. Barnes Peter J., Ito Kazuhiro, Adcock Ian M. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet. 2004 Feb 28;363(9410):731–733. doi: 10.1016/S0140-6736(04)15650-X. [DOI] [PubMed] [Google Scholar]
  7. Burge P. S., Calverley P. M. A., Jones P. W., Spencer S., Anderson J. A. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax. 2003 Aug;58(8):654–658. doi: 10.1136/thorax.58.8.654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Burge P. S., Calverley P. M., Jones P. W., Spencer S., Anderson J. A., Maslen T. K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000 May 13;320(7245):1297–1303. doi: 10.1136/bmj.320.7245.1297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Calverley P. M., Boonsawat W., Cseke Z., Zhong N., Peterson S., Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003 Dec;22(6):912–919. doi: 10.1183/09031936.03.00027003. [DOI] [PubMed] [Google Scholar]
  10. Calverley Peter M. A., Spencer Sally, Willits Lisa, Burge P. Sherwood, Jones Paul W., IOSLDE Study Group Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest. 2003 Oct;124(4):1350–1356. doi: 10.1378/chest.124.4.1350. [DOI] [PubMed] [Google Scholar]
  11. Calverley Peter, Pauwels Romain, Vestbo Jørgen, Jones Paul, Pride Neil, Gulsvik Amund, Anderson Julie, Maden Claire, TRial of Inhaled STeroids ANd long-acting beta2 agonists study group Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003 Feb 8;361(9356):449–456. doi: 10.1016/S0140-6736(03)12459-2. [DOI] [PubMed] [Google Scholar]
  12. Chalmers G. W., Macleod K. J., Little S. A., Thomson L. J., McSharry C. P., Thomson N. C. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax. 2002 Mar;57(3):226–230. doi: 10.1136/thorax.57.3.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Culpitt S. V., Maziak W., Loukidis S., Nightingale J. A., Matthews J. L., Barnes P. J. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1635–1639. doi: 10.1164/ajrccm.160.5.9811058. [DOI] [PubMed] [Google Scholar]
  14. Domingo-Salvany Antònia, Lamarca Rosa, Ferrer Montserrat, Garcia-Aymerich Judith, Alonso Jordi, Félez Miquel, Khalaf Ahmad, Marrades Ramon M., Monsó Eduard, Serra-Batlles Joan. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002 Sep 1;166(5):680–685. doi: 10.1164/rccm.2112043. [DOI] [PubMed] [Google Scholar]
  15. Hankinson J. L., Odencrantz J. R., Fedan K. B. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999 Jan;159(1):179–187. doi: 10.1164/ajrccm.159.1.9712108. [DOI] [PubMed] [Google Scholar]
  16. Highland Kristin B., Strange Charlie, Heffner John E. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med. 2003 Jun 17;138(12):969–973. doi: 10.7326/0003-4819-138-12-200306170-00008. [DOI] [PubMed] [Google Scholar]
  17. Hospers J. J., Postma D. S., Rijcken B., Weiss S. T., Schouten J. P. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet. 2000 Oct 14;356(9238):1313–1317. doi: 10.1016/S0140-6736(00)02815-4. [DOI] [PubMed] [Google Scholar]
  18. Jones P. W., Willits L. R., Burge P. S., Calverley P. M. A., Inhaled Steroids in Obstructive Lung Disease in Europe study investigators Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J. 2003 Jan;21(1):68–73. doi: 10.1183/09031936.03.00013303. [DOI] [PubMed] [Google Scholar]
  19. Kanner R. E., Connett J. E., Altose M. D., Buist A. S., Lee W. W., Tashkin D. P., Wise R. A. Gender difference in airway hyperresponsiveness in smokers with mild COPD. The Lung Health Study. Am J Respir Crit Care Med. 1994 Oct;150(4):956–961. doi: 10.1164/ajrccm.150.4.7921469. [DOI] [PubMed] [Google Scholar]
  20. Keatings V. M., Jatakanon A., Worsdell Y. M., Barnes P. J. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med. 1997 Feb;155(2):542–548. doi: 10.1164/ajrccm.155.2.9032192. [DOI] [PubMed] [Google Scholar]
  21. Kuschner W. G., D'Alessandro A., Wong H., Blanc P. D. Dose-dependent cigarette smoking-related inflammatory responses in healthy adults. Eur Respir J. 1996 Oct;9(10):1989–1994. doi: 10.1183/09031936.96.09101989. [DOI] [PubMed] [Google Scholar]
  22. Lam Stephen, leRiche Jean C., McWilliams Annette, Macaulay Calum, Dyachkova Yulia, Szabo Eva, Mayo John, Schellenberg Robert, Coldman Andy, Hawk Ernest. A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res. 2004 Oct 1;10(19):6502–6511. doi: 10.1158/1078-0432.CCR-04-0686. [DOI] [PubMed] [Google Scholar]
  23. Maestrelli P., El Messlemani A. H., De Fina O., Nowicki Y., Saetta M., Mapp C., Fabbri L. M. Increased expression of heme oxygenase (HO)-1 in alveolar spaces and HO-2 in alveolar walls of smokers. Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 1):1508–1513. doi: 10.1164/ajrccm.164.8.2011083. [DOI] [PubMed] [Google Scholar]
  24. Murray C. J., Lopez A. D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997 May 24;349(9064):1498–1504. doi: 10.1016/S0140-6736(96)07492-2. [DOI] [PubMed] [Google Scholar]
  25. Pauwels R. A., Buist A. S., Calverley P. M., Jenkins C. R., Hurd S. S., GOLD Scientific Committee Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001 Apr;163(5):1256–1276. doi: 10.1164/ajrccm.163.5.2101039. [DOI] [PubMed] [Google Scholar]
  26. Pauwels R. A., Löfdahl C. G., Laitinen L. A., Schouten J. P., Postma D. S., Pride N. B., Ohlsson S. V. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999 Jun 24;340(25):1948–1953. doi: 10.1056/NEJM199906243402503. [DOI] [PubMed] [Google Scholar]
  27. Pedersen B., Dahl R., Karlström R., Peterson C. G., Venge P. Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking. Am J Respir Crit Care Med. 1996 May;153(5):1519–1529. doi: 10.1164/ajrccm.153.5.8630596. [DOI] [PubMed] [Google Scholar]
  28. Sin Don D., McAlister Finlay A., Man S. F. Paul, Anthonisen Nick R. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA. 2003 Nov 5;290(17):2301–2312. doi: 10.1001/jama.290.17.2301. [DOI] [PubMed] [Google Scholar]
  29. Spencer S., Calverley P. M. A., Burge P. S., Jones P. W. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004 May;23(5):698–702. doi: 10.1183/09031936.04.00121404. [DOI] [PubMed] [Google Scholar]
  30. Sutherland E. R., Allmers H., Ayas N. T., Venn A. J., Martin R. J. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2003 Nov;58(11):937–941. doi: 10.1136/thorax.58.11.937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Szafranski W., Cukier A., Ramirez A., Menga G., Sansores R., Nahabedian S., Peterson S., Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003 Jan;21(1):74–81. doi: 10.1183/09031936.03.00031402. [DOI] [PubMed] [Google Scholar]
  32. Vestbo J., Sørensen T., Lange P., Brix A., Torre P., Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999 May 29;353(9167):1819–1823. doi: 10.1016/s0140-6736(98)10019-3. [DOI] [PubMed] [Google Scholar]
  33. Yao Ruisheng, Wang Yian, Lemon William J., Lubet Ronald A., You Ming. Budesonide exerts its chemopreventive efficacy during mouse lung tumorigenesis by modulating gene expressions. Oncogene. 2004 Oct 7;23(46):7746–7752. doi: 10.1038/sj.onc.1207985. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES